Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies
Open accessAbstract
Circulating tumor DNA can be detected in the blood and body fluids of patients using ultrasensitive technologies, which have the potential to improve cancer diagnosis, risk stratification, noninvasive tumor profiling, and tracking of treatment response and disease recurrence. As we begin to apply “liquid biopsy” strategies in children with cancer, it is important to tailor our efforts to the unique genomic features of these tumors and address the technical and logistical challenges of integrating biomarker testing. This article reviews the literature demonstrating the feasibility of applying liquid biopsy to pediatric solid malignancies and suggests new directions for future studies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Circulating tumor DNA is a candidate biomarker that could help guide prognosis, disease monitoring, and identification of actionable genomic variants.
“Circulating tumor DNA (ctDNA) is a candidate biomarker with the potential to guide prognostication, disease monitoring, and identification of actionable genomic variants.6”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 107 · Cited by 72
Research works printed but not linked: 2
- [1]Mandel P, METAIS P. Comptes rendus des seances de la Societe de biologie et de ses filiales. 1948; 142(3-4): 241– 243. 18875018
- [103]Chicard M, Colmet-Daage L, Clement N, Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2018; 24(4): 939– 949. doi: 10.1158/1078-0432.CCR-17-1586 29191970 · DOI
- Authors
- Abbou, S. D., Shulman, D. S., DuBois, S. G., & Crompton, B. D.
- Affiliations
- Institut Gustave Roussy (FR)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
- Broad Institute (US)
- Corresponding author
- Crompton, Brian D.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2019-01-06
- Volume
- 66
- Issue
- 5
- Pages
- e27595-e27595
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- PMC
- PMC6550461
- OpenAlex
- W2910054855
- Cited by
- 72
- References
- 107
- Citations by year
- 2026: 9 · 2025: 3 · 2024: 12 · 2023: 16 · 2022: 9 · 2021: 9 · 2020: 10 · 2019: 4
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Pediatric Blood & Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K08 CA188073‐03)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Screening and Diagnostics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Acute Lymphoblastic Leukemia research
- Keywords
- circulating tumor DNA, liquid biopsy, pediatric solid tumors, tumor markers, treatment response monitoring, recurrence, cancer risk stratification, cancer diagnosis
- MeSH terms
- Liquid Biopsy, Circulating Tumor DNA, Humans, Neoplasms, Biomarkers, Tumor, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
